Last reviewed · How we verify
Vehicle (TID)
Vehicle (TID) is a treatment that does not have a known mechanism of action.
At a glance
| Generic name | Vehicle (TID) |
|---|---|
| Also known as | Vehicle |
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a vehicle, it is used as a control group in clinical trials and does not have a specific therapeutic effect.
Approved indications
Common side effects
Key clinical trials
- A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease. (PHASE2)
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) (PHASE2, PHASE3)
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) (PHASE3)
- Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis (PHASE2)
- JN002 for the Treatment of Dry Eye Disease (EARLY_PHASE1)
- Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PHASE3)
- Propranolol Treatment for Postoperative Chylothorax (PHASE1, PHASE2)
- Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle (TID) CI brief — competitive landscape report
- Vehicle (TID) updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI